← Leaderboards
Catherine Chappell
Magee-Women'S Res Inst And Foundation
$994,933
Attributed
$1,462,904
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $546K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,462,904 · 3
By mechanism
R21$916,938 · 2
R44$545,966 · 1
Top collaborators
- Beatrice A. Chen1 shared
- Ann E. Jerse1 shared
- Barbara Best North1 shared
- Urvi M. Parikh1 shared
- Gail S Prins1 shared
- Mary B Weitzel1 shared
Most similar at Magee-Women'S Res Inst And Foundation
Same institution · by research overlap
- David R Friend$4,956,000
- Elizabeth E Krans$9,084,307
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyPreventWomanDoseAdherencePharmaceutical PreparationsPreclinical EvaluationSamplingEvaluationDrug KineticsGrowthGenotypeChronic Hepatitis CGestational AgeEnsureHealthcareHepatitis CDrug ExposureBaseAreaAge-MonthsBirthAntiviral TherapyAntiviral Agents
Grant awards (5)
First in Human Clinical Trial of a Contraceptive MPT YASO GEL$545,966
R44 · FY2025 · HD
A Phase 1 PK and Safety Study of Velpatasvir/Sofosbuvir for Chronic Hepatitis C Infection in Pregnant Women$197,741
R21 · FY2021 · HD · contact PI
A Phase 1 PK and Safety Study of Velpatasvir/Sofosbuvir for Chronic Hepatitis C Infection in Pregnant Women$267,981
R21 · FY2020 · HD · contact PI
A Phase 1 Pharmacokinetic Trial of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination in Pregnant Women with Chronic Hepatitis C Virus Infection$161,520
R21 · FY2017 · HD · contact PI
A Phase 1 Pharmacokinetic Trial of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination in Pregnant Women with Chronic Hepatitis C Virus Infection$289,696
R21 · FY2016 · HD · contact PI